Valuation: ImmuPharma plc

Market Cap 20.54M 27.13M 24.24M 22.61M 38.69M 2.62B 38.97M 272M 106M 1.33B 102M 99.64M 4.29B P/E 2024
-2.01x
P/E 2025 -16.8x
Enterprise Value 19.19M 25.34M 22.64M 21.13M 36.14M 2.45B 36.41M 254M 99.18M 1.25B 95.14M 93.08M 4.01B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
95.04%
Yield 2024 *
-
Yield 2025 -
1 day-3.95%
1 week+1.08%
Current month+1.08%
1 month-17.88%
3 months-18.89%
6 months-27.64%
Current year-47.02%
1 week 3.25
Extreme 3.25
3.98
1 month 3.02
Extreme 3.0223
4.1
Current year 3.02
Extreme 3.0223
11
1 year 3.02
Extreme 3.0223
14
3 years 0.82
Extreme 0.822
19.4
5 years 0.82
Extreme 0.822
19.4
10 years 0.82
Extreme 0.822
193.74
Manager TitleAgeSince
Chief Executive Officer 70 30/07/2021
Director of Finance/CFO - 03/12/2024
Chief Tech/Sci/R&D Officer - 01/09/2025
Director TitleAgeSince
Director/Board Member 60 29/07/2021
Chairman 70 30/09/2015
Director/Board Member 62 16/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/4/24 Free

Director

3,000,000 0.7204%
19/4/24 Free

Director

2,000,000 0.4803%
22/12/22 Free

Chief Executive Officer

1,800,000 0.5399%
Change 5-day change 1-year change 3-year change Capi.($)
-3.95%+1.08%-70.93%+60.24% 28.4M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-1.16%+23.36%+79.34% 58.81B
+0.17%-1.16%+3.59%+34.55% 48.45B
-0.31%-2.08%+331.61%+689.16% 42.84B
-0.64%-3.78%+28.79%+29.64% 42.79B
+0.38%-0.80%+6.26%+110.08% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-1.07%-2.82%-9.93%-12.61% 24.05B
Average -0.35%+0.28%+40.63%+116.35% 39.43B
Weighted average by Cap. +0.53%-0.54%+55.88%+128.93%

Financials

2024 2025
Net sales - -
Net income -2.48M -3.28M -2.93M -2.73M -4.68M -317M -4.71M -32.86M -12.84M -161M -12.31M -12.05M -519M -1.81M -2.39M -2.13M -1.99M -3.4M -231M -3.43M -23.92M -9.34M -117M -8.96M -8.77M -378M
Net Debt -237K -313K -280K -261K -446K -30.27M -450K -3.13M -1.22M -15.39M -1.17M -1.15M -49.48M -1.35M -1.79M -1.6M -1.49M -2.55M -173M -2.57M -17.89M -6.99M -87.86M -6.7M -6.56M -282M
Projected Income Statement - Annual - ImmuPharma plc
Logo ImmuPharma plc
ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Employees
7
Date Price Change Volume
08/10/26 GBX 3.285 -3.95% 4,594,498
06/10/26 GBX 3.420 +4.43% 4,540,917
05/10/26 GBX 3.275 -0.76% 818,143
02/10/26 GBX 3.300 -5.58% 2,991,041
01/10/26 GBX 3.495 +7.54% 1,178,422